Evaxion Biotech A/S — Form 6-K Summary
Reporting period: Form 6-K filed March 22, 2022, for the month of March 2022. The filing identifies an attached press release reporting financial results for the three months and year ended December 31, 2021.
Business Context
Evaxion Biotech A/S is a foreign private issuer headquartered in Hørsholm, Denmark, and files annual reports on Form 20-F. The filing contains the cover report and references Exhibit 99.1, a March 22, 2022 press release.
Financial Metrics
The provided filing text does not include the referenced press release or its financial statements. Accordingly, revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, operating expenses, and other financial metrics are not stated.
Material Changes Versus Prior Period
The filing text does not provide comparative financial data or a clear description of material changes versus the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide management guidance, outlook commentary, risk updates, contingencies, or information on unusual items. These matters may be addressed in Exhibit 99.1, which is not included in the supplied content.
Key Facts to Verify
- Obtain and review Exhibit 99.1, the March 22, 2022 financial-results press release.
- Verify the reported financial results for the three months and year ended December 31, 2021.
- Confirm cash, liquidity runway, debt, operating cash flow, and financing activities.
- Review management’s outlook, development-program updates, risks, and any contingencies.